Shares of Frequency Therapeutics FREQ surged 77.48% on Friday, after management announced that the company entered into a definitive agreement with RNA editing company, Korro Bio, to merge in an ...

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with ...

(RTTNews) - Korro Bio, Inc., an RNA editing firm, and Frequency Therapeutics, Inc. (FREQ), announced on Friday that they have signed a deal to combine the two firms in an all-stock transaction. The ...

A pending reverse merger with troubled Frequency Therapeutics is giving new meaning to Korro Bio’s slogan, “Edit the message. Rewrite the future.” For Korro, a developer of RNA-edited therapies, the ...

Merger aims to advance RNA editing programs. Korro Bio, a ribonucleic (RNA) editing organization, and Frequency Therapeutics Inc., have announced plans to merge into one company as part of an ...

Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under ...

CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.

Following the reverse stock split and the closing of the merger, there are approximately 8,001,283 shares of the combined company's common stock outstanding, with prior Frequency stockholders owning ...

CAMBRIDGE & LEXINGTON, Mass., July 14, 2023--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.